Article Details
Retrieved on: 2024-07-26 15:26:42
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA approval of deuruxolitinib, a Janus kinase inhibitor developed by Sun Pharma, as a treatment for moderate to severe alopecia areata (AA). The article also highlights the effectiveness of other JAK inhibitors like baricitinib and the potential link between autoimmune diseases such as AA and increased prominence post-COVID-19 outbreaks. The tags reflect the focus on hair loss treatments and scientific compounds.
Article found on: www.ajmc.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here